Cramer: Hewlett's Back
Health Care: Drugs
Zalicus Inc. (ZLCS: NASDAQ)
$0.60 0.00 | -0.34%
05/23/13 - 01:09 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 4.53M | 2.75M | 2.82M | 8.78M |
| Receivables | 3.04M | 1.89M | 1.60M | 2.93M |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 38.37M | 51.21M | 47.84M | 32.42M |
| Property, Plant & Equipment, Gross | 13.73M | 15.10M | 15.58M | 14.77M |
| Accumulated Depreciation & Depletion | 10.19M | 9.84M | 8.68M | 6.39M |
| Property, Plant & Equipment, Net | 3.54M | 5.26M | 6.90M | 8.38M |
| Intangibles | 17.65M | 21.55M | 26.69M | 45.42M |
| Other Non-Current Assets | 1.82M | 1.87M | 1.24M | 1.93M |
| Total Non-Current Assets | 23.01M | 28.68M | 34.83M | 55.73M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 61.38M | 79.88M | 82.67M | 88.15M |
| Accounts Payable | 3.26M | 1.74M | 1.84M | 4.27M |
| Short Term Debt | 6.61M | 4.32M | 557.00K | 284.00K |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 19.63M | 15.54M | 9.04M | 14.07M |
| Long Term Debt | 8.77M | 15.10M | 2.52M | 0.00 |
| Deferred Income Taxes | 457.00K | 605.00K | 743.00K | 775.00K |
| Other Non-Current Liabilities | 614.00K | 3.56M | 5.93M | 18.67M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 10.72M | 20.43M | 10.64M | 21.17M |
| Total Liabilities | 30.35M | 35.97M | 19.67M | 35.24M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 31.03M | 43.91M | 63.00M | 52.91M |
| Common Par | 127.00K | 99.00K | 89.00K | 118.00K |
| Additional Paid In Capital | 371.91M | 340.52M | 317.58M | 272.40M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -341.02M | -296.70M | -254.65M | -219.61M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 10.00K | -8.00K | -20.00K | -2.00K |
| Total Capitalization | 39.80M | 59.01M | 65.52M | 52.91M |
| Total Equity | 31.03M | 43.91M | 63.00M | 52.91M |
| Total Liabilities & Stock Equity | 61.38M | 79.88M | 82.67M | 88.15M |
| Total Common Shares Outstanding | 127.02M | 99.24M | 89.11M | 117.83M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 117.32M | 97.35M | 82.66M | 37.34M |
| Diluted Weighted Shares Outstanding | 117.32M | 97.35M | 82.66M | 37.49M |
| Number of Employees | 36 | 46 | 58 | 51 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with ZLCS
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- UserBiotech88
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- UserTrack1
- ContributorStocks Under-$10 Setting Up...
- User0730
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Setting Up...
Latest ZLCS Headlines from TheStreet
- 5 Stocks Under $10 Set to Soar Higher 01.31.13 | 01:01 pm
- Acadia Pharma Selling Stock Ahead of Key Study Results 11.06.12 | 12:11 pm
- 8 Stocks Under $10 Making Big Moves 08.30.12 | 02:08 pm
- 5 Stocks Poised for Breakouts 08.10.12 | 01:08 pm
- 5 Stocks Under $10 Set to Soar 07.26.12 | 12:07 pm
- Horizon Pharma: Rayos FDA Approval Thursday Seems Likely 07.25.12 | 10:07 am
- Biotech Stock Mailbag: Zalicus, Amarin 07.13.12 | 06:07 am
- 7 Stocks Under $10 Streaking Higher 06.07.12 | 04:06 pm
- 22 Biopharma Stocks With Breakout Potential in 2012 05.22.12 | 08:05 am
- 8 Stocks Under $10 Moving Higher 03.20.12 | 12:03 pm
Press Releases for ZLCS
- Zalicus Presents Data Demonstrating Advantages Of State-Dependent Ion Channel Screening - Business Wire 03.19.13 | 08:03 am
- Zalicus Reports Financial Results For The Fourth Quarter And Year End 2012 - Business Wire 03.06.13 | 07:03 am
- Zalicus Granted Composition-of-Matter Patent For Z944 - Business Wire 02.20.13 | 08:02 am
- Zalicus To Present At The 2013 BIO CEO & Investor Conference - Business Wire 02.05.13 | 08:02 am
- Zalicus Initiates The Second Of Two Phase 2a Studies With Z160 - Business Wire 01.03.13 | 07:01 am
- Zalicus To Present At The Oppenheimer 23rd Annual Healthcare Conference - Business Wire 12.05.12 | 04:12 pm
- Zalicus’ Z160 For Chronic Neuropathic Pain Selected As A Top 10 Project To Watch - Business Wire 11.27.12 | 08:11 am
- Zalicus Reports Financial Results For The Third Quarter 2012 - Business Wire 11.08.12 | 07:11 am
- Zalicus Licensee, Sanofi, Provides Status Update On Prednisporin (FOV1101) - Business Wire 10.25.12 | 07:10 am
- Zalicus Reports Top Line Phase 2b Trial Results With Synavive In Rheumatoid Arthritis - Business Wire 09.10.12 | 08:09 am
Partner Headlines for ZLCS
- A Study Of 3 Biotechs - A Story Of Hope, Potential And Partnerships - Seeking Alpha 03.18.13 | 09:03 am
- Under Construction Rehash: Buy Acadia And Astex - Seeking Alpha 09.20.12 | 09:09 am
- UPDATE: Rodman & Renshaw Downgrades Zalicus to Market Perform on Synavive Failure - Benzinga 09.11.12 | 01:09 pm
- Morning Market Losers - Benzinga 09.10.12 | 09:09 am
- Buy Zalicus For A 120% Upside - Seeking Alpha 09.05.12 | 09:09 am
- Investing in Biotech Stocks? The Journey to Profits Requires a Good GPS - NASDAQ 08.31.12 | 04:08 pm
- Zalicus: When Push Comes To Shove - Seeking Alpha 08.31.12 | 09:08 am
- Why Zalicus Buyers See $3 Again - Seeking Alpha 08.08.12 | 09:08 am
- 3 Rising Biotech Stars All Under $2/Share - Seeking Alpha 06.18.12 | 09:06 am
- Look For These 5 Biotech Stocks Heading North - Seeking Alpha 06.07.12 | 09:06 am
